Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

NCT03356860 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Triple Negative Breast Cancer
Luminal B

Interventions

DRUG: Paclitaxel
DRUG: Epirubicin
DRUG: Cyclophosphamide
DRUG: Durvalumab

Sponsor

Grand Hôpital de Charleroi

Collaborators

[object Object]